Icosavax, Inc. (ICVX)
| Market Cap | 766.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.71M |
| Shares Out | 50.09M |
| EPS (ttm) | -2.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,315,217 |
| Open | 15.40 |
| Previous Close | 15.31 |
| Day's Range | 15.31 - 15.40 |
| 52-Week Range | 4.75 - 16.11 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 25.00 (+63.29%) |
| Earnings Date | Mar 28, 2024 |
About ICVX
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. [Read more]
Financial Performance
In 2022, Icosavax's revenue was $582,000, a decrease of -92.54% compared to the previous year's $7.80 million. Losses were -$91.76 million, 37.0% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ICVX stock is "Buy." The 12-month stock price forecast is $25.0, which is an increase of 63.29% from the latest price.
News
ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Icosavax, Inc. (NASDAQ: ICVX) to AstraZeneca for $15.00 per share in cash plus a non-trad...
ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Icosavax, Inc. (...
SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders?
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Icosavax, Inc. (NASDAQ: ICVX) breached their fiduciary dutie...
Why AstraZeneca Is Buying Icosavax For $1.1 Billion
Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine ...
Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca
MILWAUKEE , Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Icosavax (Nasdaq: ICVX) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca. Cl...
AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout
Seattle-based Icosavax, a spin-out from the University of Washington's Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.
ICVX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Icosavax, Inc. (NASDAQ: ICVX) to AstraZeneca for $15.00 per share in cash plus a non-trad...
This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal
AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developi...
AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-...
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
- Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity value of up to $1.1 bill...
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icos...
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV -
Icosavax to Participate in the Jefferies London Healthcare Conference
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines agains...
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines agains...
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines again...
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults -
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
- In new data from Icosavax's IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) -
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nas...
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – – IVX-A12 was generally well tolerated with no vaccine-related SAEs – – First demonstration of hMPV vaccin...
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term investm...
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate -